July 21, 2026 expert reaction to a multi-target trial emulation study looking at GLP- 1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disord ...

ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights.

<li class="FC"><a href="../Library%20Types/LGF_BinaryMaskCompare.htm" title="LGF_BinaryMaskCompare (FC / 1.0.0)" target="_parent">LGF_BinaryMaskCompare (FC / 1.0.0 ...

Despite being granted a second opportunity to beef up their comparative fund argument that fiduciaries’ choice of a stable value fund was imprudent, the plaintiffs offered only a “barebones” ...

Rebuked by appeals court for "abuse of discretion" in Trump administration contempt probe, judge risks second rebuke from ...

Final trial results add to evidence supporting use in tots who remain at increased risk ...

Patients with no other options are watching an agency turn on its own scientists — and the trust that took a century to build ...

Abstract: This paper presents an automated design method for a Strong-ARM dynamic comparator. The dynamic characteristics of the dynamic comparator are analyzed and fitted into static characteristics, ...

Biopharma companies must weigh the operational complexity of continuous bioprocess against its potential productivity gains.

A federal appeals court has upheld the dismissal of an age discrimination lawsuit brought by a former security officer ...

How can human biology data improve target selection? Learn how one discovery programme identified a potential new treatment ...